Defining paediatric metabolic (dysfunction)-associated fatty liver disease: an international expert consensus statement.
Adolescent
Adult
Child
Consensus
Disease Progression
Female
Humans
Insulin Resistance
/ physiology
Interdisciplinary Communication
Male
Metabolic Syndrome
/ complications
Non-alcoholic Fatty Liver Disease
/ diagnosis
Obesity
/ complications
Prevalence
Prognosis
Randomized Controlled Trials as Topic
Risk Factors
Severity of Illness Index
Journal
The lancet. Gastroenterology & hepatology
ISSN: 2468-1253
Titre abrégé: Lancet Gastroenterol Hepatol
Pays: Netherlands
ID NLM: 101690683
Informations de publication
Date de publication:
10 2021
10 2021
Historique:
received:
16
03
2021
revised:
17
05
2021
accepted:
18
05
2021
pubmed:
9
8
2021
medline:
2
10
2021
entrez:
8
8
2021
Statut:
ppublish
Résumé
The term non-alcoholic fatty liver disease (NAFLD), and its definition, have limitations for both adults and children. The definition is most problematic for children, for whom alcohol consumption is usually not a concern. This problematic definition has prompted a consensus to rename and redefine adult NAFLD associated with metabolic dysregulation to metabolic (dysfunction)-associated fatty liver disease (MAFLD). Similarities, distinctions, and differences exist in the causes, natural history, and prognosis of fatty liver diseases in children compared with adults. In this Viewpoint we, an international panel, propose an overarching framework for paediatric fatty liver diseases and an age-appropriate MAFLD definition based on sex and age percentiles. The framework recognises the possibility of other coexisting systemic fatty liver diseases in children. The new MAFLD diagnostic criteria provide paediatricians with a conceptual scaffold for disease diagnosis, risk stratification, and improved clinical and multidisciplinary care, and they align with a definition that is valid across the lifespan.
Identifiants
pubmed: 34364544
pii: S2468-1253(21)00183-7
doi: 10.1016/S2468-1253(21)00183-7
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
864-873Commentaires et corrections
Type : CommentIn
Type : CommentIn
Type : CommentIn
Informations de copyright
Copyright © 2021 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests JG reports personal fees from Gilead, Pfizer, AstraZeneca, Pharmaxis, Cincera, Novartis, Roche, Intercept, Novo, and MSD during the writing of the report. LAB reports personal fees from Novo Nordisk. CM reports personal fees from Evira and Itrim, and grants and personal fees from Novo Nordisk. ME reports personal fees from Pfizer. The other authors declare no competing interests.